Target RWE Publications

Total Publications

175

Manuscripts

Oral
Presentations

Poster
Presentations

What's New

Dermatology

Benjamin Ungar, MD; Helen Tran, PharmD; Ayman Grada, MD; Claire Bristow, PhD; Ernest H. Law, PharmD, PhD; Liza Takiya, PharmD; Breda Munoz Hernandez, PhD; Keith Knapp, PhD; Julie M. Crawford, MD; Maria Hordinsky, MD. Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA. AAD Conference. ePoster. March, 2024.

Dermatology

Alexa B. Kimball, MD, MPH; Dhaval Patil, PharmD, MS; Akash Danavar, PharmD, MS, MPH, MA; Claire C. Bristow, PhD, MPH, MSc; Jane Mast, PhD, DMSc, MPAS; Brenton Bialik, PharmD; Feng Yu, PhD; Keith Knapp, PhD; Julie M. Crawford, MD; Tiffany Mayo, MD. Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS. Maui Derm Hawaii. Poster Presentation. January, 2024.

Nonalcoholic Steatohepatitis (NASH)

Jesse Fishman, Heather L. Morris, Andrea R. Mospan, Derek Gazis, Yestle Kim, A. Sidney Barritt IV, Arun Sanyal, Philip N. Newsome, Rohit Loomba, on behalf of TARGET-NASH Investigators. A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH. NASH-TAG Conference. Poster Presentation. January, 2024.

Nonalcoholic Steatohepatitis (NASH)

Jesse Fishman; Heather L. Morris; Breda Munoz; Andrea R. Mospan; Yestle Kim; Rohit Loomba; A. Sidney Barritt IV; Philip N. Newsome; on behalf of TARGET-NASH Investigators. Non-invasive tests as a prediction tool to assess MASH resolution score. NASH TAG Conference. Poster Presentation. January, 2024.

Rheumatology

Min Kim, Vanessa C. Brunetti, Felicia Cosman, Jeffrey Curtis, E Michael Lewiecki, Matthew Phelan, Peter Samai, Michele McDermott, Tzu-Chieh Lin, M Alan Brookhart and Kathleen Hurwitz. Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States. ACR Convergence. Oral Presentation. November, 2023.

Cardiovascular Disease

Fishman J, Mospan AR, Morris HL, Gazis D, Sanyal A, Newsome P, Loomba R, on behalf of TARGET-NASH Investigators. Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models. AHA Conference. Poster Presentation. November, 2023.

Clear

Publications

Nonalcoholic Steatohepatitis (NASH)

Arun J. Sanyal, Breda Munoz, Kenneth Cusi, A. Sidney Barritt IV, Mark Muthiah, Andrea R. Mospan, K. Rajender Reddy, Roberto Firpi-Morell, Paul J. Thuluvath, Kalyan Ram Bhamidimarri, Michael W. Fried, on behalf of the TARGET-NASH Investigators. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort. Clinical Gastroenterology and Hepatology, March 2023; DOI: doi.org/10.1016/j.cgh.2023.02.024.

Eduardo Castillo-Leon, Heather L. Morris, Cheryl Schoen, Jacob Bilhartz, Patrick McKiernan, Tamir Miloh, Sirish Palle, Mohammad Nasser Kabbany, Breda Munoz, Andrea R. Mospan, Bryan Rudolph, Stavra A. Xanthakos, Miriam B. Vos, TARGET-NASH Investigators. Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease. Children, March 2022; doi.org/10.3390/children9030374.

Hannah P. Kim, Michael O. Idowu, Andrea R. Mospan, Andrew G. Allmon, Michael Roden, Philip Newsome, Anna S. Lok, Paul J. Thuluvath, Jawahar Taunk, Michael W. Fried, Arun J. Sanyal, A. Sidney Barritt IV. Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis. Alimentary Pharmacology and Therapeutics, October 2021; doi.org/10.1111/apt.16674.

Mary J. Thomson, Marina Serper, Vandana Khungar, L. Michael Weiss, Huy Trinh, Roberto Firpi-Morell, Michael Roden, Rohit Loomba, A. Sidney Barritt IV, Derek Gazis, Andrea R. Mospan, Michael W. Fried, K. Rajender Reddy, Anna S. Lok. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology & Hepatology, March 2021; doi: 10.1016/j.cgh.2021.03.031. Epub ahead of print.

A. Sidney Barritt, Stephanie Watkins, Norman Gitlin, Samuel Klein, Anna S. Lok, Rohit Loomba, Cheryl Schoen, K. Rajender Reddy, Huy Ngoc Trinh, Andrea R. Mospan, Miriam B. Vos, L. Michael Weiss, Kenneth Cusi, Brent A. Neuschwander‐Tetri, Arun J. Sanyal. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study. Hepatology Communications, February 2021; doi.org/10.1002/hep4.1689.

Miguel H. Malespin, Alfred Sidney Barritt IV, Stephanie E. Watkins, Cheryl Schoen, Monica A. Tincopa, Karen D. Corbin, Andrea R. Mospan, Breda Munoz, Huy N. Trinh, L Michael Weiss, K Rajender Reddy, Rohit Loomba, Nyingi Kemmer, Anna S. Lok. Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort. Clinical Gastroenterology and Hepatology, January 2021; doi.org/10.1016/j.cgh.2021.01.023

Moon A.M., Watkins S.E., Lok A.S., Firpi-Morell R.J., Trinh H.N., Kupec J.T., Schoen C., Neuschwander-Tetri B.A., Barritt A.S. IV. Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease. Digestive Diseases, September 2020. Published via Advanced Release (accepted, unedited manuscript) doi: 10.1159/000511074.

Ethan M. Weinberg, Huy N. Trinh, Roberto J. Firpi, Kalyan Ram Bhamidimarri, Samuel Klein, Jonathan Durlam, Stephanie Watkins, K. Rajender Reddy, Michael Weiss, Richard C. Zink, Anna S. Lok. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases. Clinical Gastroenterology and Hepatology, July 2020; doi: 10.1016/j.cgh.2020.06.066.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri B, Sanyal A. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study. Contemporary Clinical Trials, October 2017; 61: 33-38; doi: 10.1016/j.cct.2017.07.015.

9 Dermatology

Lara Wine Lee, Keith Knapp, Breda Munoz, Anthony Perez, Chibuzo Obi, Brian Calimlim, Ayman Grada, Jonathan I Silverberg. Healthcare disparities in atopic dermatitis: insights from TARGET-DERM registry. British Journal of Dermatology, June 2023; doi.org/10.1093/bjd/ljad162.042.

Jonathan I Silverberg, Keith D. Knapp, Breda Munoz, Julie M. Crawford, Brian Calimlim, Ayman Grada, Amy S. Paller, on behalf of the TARGET-DERM Investigators. The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: real-world insights from TARGET-DERM AD. British Journal of Dermatology, June 2023; doi.org/10.1093/bjd/ljad162.041.

Jonathan I. Silverberg, MD, PhD, MPH; Brenda Simpson, MD; Katrina Abuabara, MD; Emma Guttman-Yassky, MD, PhD; Brian Calimlim, DrPH; Colleen Wegzyn, PharmD; Whitney Krueger, PhD; Amy Gamelli, PhD; Breda Munoz, PhD; Rachel W. Faller, PhD; Julie M. Crawford, MD; Ayman Grada, MD; Lawrence F. Eichenfield, MD; on behalf of the TARGET-DERM Investigators. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort. Journal of the American Academy of Dermatology, May 2023; doi.org/10.1016/j.jaad.2023.04.052.

Emma Guttman-Yassky, Jonathan Bar, Camille Rothenberg Lausell, Lawrence F. Eichenfield, Ayman Grada, Katrina Abuabara, M. Shane Chapman, Brian Calimlim, Colleen Wegzyn, Amy Gamelli, Whitney Krueger, Breda Munoz, Keith Knapp, Rachel W. Faller, Julie M. Crawford, Jonathan I. Silverberg. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry. Journal of Drugs in Dermatology, April 2023; doi:10.36849/JDD.7473.

Katrina Abuabara, Lawrence F. Eichenfield, Robert Bissonnette, Jonathan I. Silverberg, Jerry Bagel, Emma Guttman-Yassky, Diamant Thaci, Eric L. Simpson, John E. Harris, James Krueger, Daniela E. Myers, Amy Gamelli, Marina Milutinovic, Anne Parneix, Julie M. Crawford, Breda Munoz, Amy S. Paller. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort. Journal of the American Academy of Dermatology, December 2022; doi.org/10.1016/j.jaad.2022.08.065.

Katrina Abuabara, Jonathan I Silverberg, Eric L Simpson, Amy S Paller, Lawrence F Eichenfield, Robert Bissonnette, James Krueger, John E. Harris, Laura Dalfonso, Stephanie E Watkins, Julie M Crawford, D Thaci, Emma Guttman-Yassky. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open, November 2020; 10:e039928. doi: 10.1136/bmjopen-2020-039928.

6 Gastroenterology

Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, Bruce E. Sands, John S. Hanson, David T. Rubin, Marla C. Dubinsky, Miguel Regueiro, Derek Gazis, Julie M. Crawford and Millie D. Long. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET‑IBD. BMC Gastroenterology, February 2022; doi.org/10.1186/s12876-022-02143-x.

Barnes, Edward L., Hanson, John S., Regueiro, Miguel D., Saha, Sumona, Sands, Bruce E., Rubin, David T., Dubinsky, Marla C., Siegel, Corey A., Gazis, Derek R., Crawford, Julie M., Long, Millie D. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, June 2021; doi: 10.1097/MCG.0000000000001557. Volume Publish Ahead of Print.

Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, Bruce E. Sands, John S. Hanson, Miguel Regueiro, David T Rubin, Marla C. Dubinsky, Derek R. Gazis, Laura Dalfonso, Janet S Hildebrand, Julie M. Crawford, Millie D. Long. Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD. Crohn's & Colitis 360, otab023, May 2021; doi.org/10.1093/crocol/otab023.

3 Primary Biliary Cholangitis (PBC)

Marlyn J. Mayo, Elizabeth Carey, Helen T. Smith, Andrea R. Mospan, Megan M. McLaughlin, April Thompson, Heather L. Morris, Robert A. Sandefur, Christopher L. Bowlus, & on behalf of the TARGET-PBC Investigators, Cynthia Levy. Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary. Future Rare Diseases, November 2023; doi.org/10.2217/frd-2023-0016.

Marlyn J. Mayo, Elizabeth Carey, Helen T. Smith, Andrea R. Mospan, Megan McLaughlin, April Thompson, Heather L. Morris, Robert Sandefur, W. Ray Kim, Christopher Bowlus, TARGET-PBC Investigators, Cynthia Levy. Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. Digestive Diseases and Sciences, June 2022; doi.org/10.1007/s10620-022-07581-x

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW. A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale. Hepatology Communications, March 2018; 2(4) 484-491; doi.org/10.1002/hep4.1173.

3 Hepatocellular Carcinoma (HCC)

Cabrera, R., Singal, A.G., Colombo, M., Kelley, R., Lee, H., Mospan, A.R., Meyer, T., Newell, P., Parikh, N.D., Sangro, B., Reddy, K.R., Watkins, S., Zink, R.C. and Di Bisceglie, A.M. A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC. Hepatology Communications, December 2020; doi.org/10.1002/hep4.1652.

1 Oncology

Vikram M. Narayan, Despina Siolas, Eric S. Meadows, Vladimir Turzhitsky, Arthur Sillah, Kentaro Imai, Andrew J. McMurry, and Haojie Li. Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non–Muscle-Invasive Bladder Cancer. JCO Clinical Cancer Informatics, October 2023; DOI: 10.1200/CCI.23.00096.

Leah J. McGrath, Rohini K. Hernandez, Robert Overman, Diane Reams, Alexander Liede, M. Alan Brookhart, Elizabeth O’Donnell. Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States. Cancer Medicine, December 2018; doi.org/10.1002/cam4.1869

McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA, Brookhart MA, Hernandez RK. Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. Clinical Epidemiology, September 2018; doi.org/10.2147/CLEP.S175063.

3 Pharmacoepidemiology

Sara N. Levintow, Carrie M. Nielson, Rohini K. Hernandez, Alexander Breskin, David Pritchard, Timothy L. Lash, Kenneth J. Rothman, David Gilbertson, Paul Muntner, Cathy Critchlow, M. Alan Brookhart, Brian D. Bradbury. Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: A narrative review. Pharmacoepidemiology & Drug Safety, March 2023; doi.org/10.1002/pds.5623

Sara N Levintow, Stephanie R Reading, Sina Noshad, Sophie E Mayer, Catherine Wiener, Bassim Eledath, Jason Exter, M Alan Brookhart. Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019. Clinical Epidemiology, June 2022; doi: 10.2147/CLEP.S361258.

Sara N. Levintow, Kate K. Orroth, Alexander Breskin, Andrew S. Park, Jose H. Flores-Arredondo, Paul Dluzniewski, Ann Marie Navar, Henrik T. Sørensen, M. Alan Brookhart. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Pharmacoepidemiology & Drug Safety, December 2021; doi.org/10.1002/pds.5396.

Pardiss Kaviani, Suzanne N. Landi, Aaron McKethan, M. Alan Brookhart, Leah J. McGrath. Who are we missing? Underrepresentation of data sources used for pharmacoepidemiology research in the United States. Pharmacoepidemiology & Drug Safety, November 2020; doi.org/10.1002/pds.5087.

4 Chronic Hepatitis B (HBV)

David E. Bernstein, Huy N. Trinh, Eugene R. Schiff, Coleman I. Smith, Andrea R. Mospan, Richard C. Zink, Michael W. Fried, Anna S. Lok. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Digestive Diseases and Sciences, May 2021; doi: 10.1007/s10620-021-07033-y. Online ahead of print.

1 Real-World Evidence

Andrea R. Mospan, Heather L. Morris, Michael W. Fried. Real-world evidence in hepatocellular carcinoma. Liver International, June 2021; doi.org/10.1111/liv.14864.

1 Epidemiology

Latour CD, McGrath LJ, Clouser M, Nielson C, Yu Y, Balasubramanian A, Breskin A, Brookhart MA. Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study. Clinical Epidemiology, May 2023; doi.org/10.2147/CLEP.S406552.

Noah A Haber, ScD; Mollie E Wood, PhD; Sarah Wieten, PhD; Alexander Breskin, PhD. DAG With Omitted Objects Displayed (DAGWOOD): a framework for revealing causal assumptions in DAGs. Annals of Epidemiology, April 2022; doi.org/10.1016/j.annepidem.2022.01.001.

2 Hematology

Snell Taylor Sara J., Carrie M. Nielson, Alexander Breskin, Bradley Saul, Ying Yu, Naufil Alam, Melissa Eisen, Jane Hippenmeyer, Ann Janssens, Tomas Kozak, Helen A. Papadaki, Dominik Selleslag, Jean-Francois Viallard, Clemens Feistritzer, Georgia Kaiafa, Michael Kelsh, Karynsa Kilpatrick, M. Alan Brookhart & Leah J. McGrath. Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice. Advances in Therapy, April 2021; doi.org/10.1007/s12325-021-01727-5.

McGrath LJ, Kilpatrick K, Overman RA, Reams D, Sharma A, Altomare I, Wasser J, Brookhart MA. Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States. Clinical Epidemiology, May 2020; doi.org/10.2147/CLEP.S229266.

2 Osteoporosis

Leah J. McGrath, Leslie Spangler, Jeffrey R. Curtis, Vera Ehrenstein, Henrik T. Sørensen, Bradley Saul, Sara N. Levintow, Diane Reams, Brian D. Bradbury, M. Alan Brookhart. Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States. Pharmacoepidemiology & Drug Safety, June 2020; doi.org/10.1002/pds.5037.

1 Cardiovascular Disease

Kate K. Orroth, Sara N. Levintow, Alexander Breskin, Paul Dluzniewski, Andrew S. Park, and M. Alan Brookhart. Use of negative control outcomes to assess the comparability of treatments for hypercholesterolemia. Journal of the American College of Cardiology, May 2021; doi.org/10.1016/S0735-1097(21)02854-0.

Levintow SN, Reading SR, Saul BC, Yu Y, Reams D, McGrath LJ, Philip K, Dluzniewski PJ, Brookhart MA. Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines. Clinical Epidemiology, August 2020; doi.org/10.2147/CLEP.S259757.

2 Medicaid

David M. Anderson, MS; Rushina Cholera, MD, PhD; Alexander Breskin, PhD; Sudha R. Raman, PhD; Charlene Wong, MD, MSPH. Postpartum Medicaid enrollment and churn in North Carolina. American Journal of Obstetrics & Gynecology, July 2022; doi.org/10.1016/j.ajogmf.2022.100656.

Rushina Cholera, MD, PhD; David Anderson, MS; Sudha R. Raman, PhD; Bradley G. Hammill, DrPH; Bethany DiPrete, PhD; Alexander Breskin, PhD; Catherine Wiener, MS; Nuvan Rathnayaka; Suzanne Landi, PhD; M. Alan Brookhart, PhD; Rebecca G. Whitaker, PhD; Janet Prvu Bettger, ScD; Charlene A. Wong, MD, MSHP. Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid From 2016 to 2018. JAMA Health Forum, December 2021; doi:10.1001/jamahealthforum.2021.4283.

2 COVID-19

Alexander Breskin, Catherine Wiener, Adaora A Adimora, Robert S Brown Jr, Charles Landis, K Rajender Reddy, Elizabeth C Verna, Julie M Crawford, Andrea Mospan, Michael W Fried, M Alan Brookhart. Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation. Epidemiology, May 2023; DOI: 10.1097/EDE.0000000000001598.

Kathleen E Wirth, Jessie K Edwards, Lydia Feinstein, Alexander Breskin. When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose. Clinical Infectious Diseases, January 2023; doi: 10.1093/cid/ciac700.

Elizabeth C Verna, Charles Landis, Robert S Brown, Andrea R Mospan, Julie M Crawford, Janet S Hildebrand, Heather L Morris, Breda Munoz, Michael W Fried, K Rajender Reddy. Factors Associated with Readmission in the US Following Hospitalization with COVID-19. Clinical Infectious Diseases, May 2021; doi.org/10.1093/cid/ciab464.

Michael W. Fried, Julie M. Crawford, Andrea R. Mospan, Stephanie E. Watkins, Breda Munoz Hernandez, Richard C. Zink, Sherry Elliott, Kyle Burleson, Charles Landis, K. Rajender Reddy, Robert S. Brown, Jr. Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States. Clinical Infectious Diseases, August 2020; doi: 10.1093/cid/ciaa1268.

4 Human Immunodeficiency Virus (HIV)

Kathleen E Hurwitz, Oluwaseyi O Isehunwa, Kayla R Hendrickson, Manjeetha Jaggernath, Yolandie Kriel, Patricia M Smith, Mxolisi Mathenjwa, Kara Bennett, Christina Psaros, Jared M Baeten, David R Bangsberg, Jessica E Haberer, Jennifer A Smit, Lynn T Matthews. Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women. Frontiers in Reproductive Health, October 2023; DOI: 10.3389/frph.2023.1263422.

Lynn T. Matthews, Esther C. Atukunda, Moran Owembabazi, Kato Paul Kalyebera, Christina Psaros, Pooja Chitneni, Craig W. Hendrix, Mark A. Marzinke, Peter L. Anderson, Oluwaseyi O. Isehunwa, Kathleen E. Hurwitz, Kara Bennett, Winnie Muyindike, David R. Bangsberg, Jessica E. Haberer, Jeanne M. Marrazzo, Mwebesa Bosco Bwana. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study. PLOS Medicine, February 2023; DOI: 10.1371/journal.pmed.1004088

2

Posters, Presentations

Nonalcoholic Steatohepatitis (NASH)

NASH TAG 2024- Non-invasive tests as a prediction tool to assess MASH resolution score

NASH TAG 2024- A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH

Claudio Sartini, Bryan Rudolph, Mandy Fraessdorf, Heather L. Morris, Derek Gazis, Andrea R. Mospan, Michael W. Fried, Michael Roden, Brent Tetri, Kenneth Cusi, Philip N. Newsome, on behalf of TARGET-NASH Investigators. Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study. EASL Congress 2023. Oral Presentation. June, 2023.

Tapper E, Fishman J , Mospan AR, Morris HL, Munoz B, Newsome P, Loomba R, on behalf of TARGET NASH Investigators. NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US. ISPOR 2023. Poster Presentation. May, 2023.

ISPOR 2023- NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US

Leen Al-Sayyed MD, Heather L. Morris, Andrea R. Mospan, Breda Munoz, Sheenu Abraham, Michael W. Fried, A. Sidney Barritt IV, Brent A. Neuschwander-Tetri. The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH. AASLD Liver Meeting. Poster Presentation. November, 2022.

AASLD 2022- The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH

M.W. Fried, B. Munoz, J. Wu, K. Cusi, V. Wong, P. Mesenbrink, M. Pedrosa, A. Mospan, H.L. Morris, M. Vos, R. Loomba, A. Sanyal, on behalf of TARGET-NASH Investigators. Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks. EASL International Liver Congress. Poster Presentation. June, 2022.

ILC2022- Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks

A. Sidney Barritt IV, Gerardo Rodriguez-Araujo, Gabriel R. Quitoriano, Andrea R. Mospan, Brent A Neuschwander-Tetri, Arun J. Sanyal. Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study. Paris NASH Meeting. Virtual Poster Presentation. September, 2021.

Paris NASH 2021- Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study

Arun J. Sanyal, Meng Wang, Kenneth Cusi, A. Sidney Barritt IV, Mark Muthiah, Stephanie Watkins, K. Rajender Reddy, Roberto Firpi-Morell, Paul Thuluvath, Kalyan Ram Bhamidimarri, Michael W. Fried. A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes. AASLD. Virtual Poster. November, 2020.

AASLD 2020, A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes

Hannah P. Kim, Michael O. Idowu, Richard C. Zink, Andrea R. Mospan, Michael Roden, Philip Newsome, Anna Lok, Paul Thuluvath, Jawahar Taunk, Michael W. Fried, Arun J. Sanyal, A. Sidney Barritt IV. Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice. AASLD. Virtual Poster. November, 2020.

AASLD 2020, NASH Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice

A. Sidney Barritt IV, K. Rajender Reddy, L. Michael Weiss, Paul J. Thuluvath, Andrea R. Mospan, Cheryl Schoen, Kenneth Cusi, Arun J. Sanyal. Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study. AASLD. Virtual Poster. November, 2020.

AASLD, 2020 Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study

Peter Mesenbrink, A. Sidney Barritt IV, Rohit Loomba, Philip N. Newsome, Arun J. Sanyal, Richard C. Zink. Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH. EASL. Virtual poster presentation. August, 2020.

EASL 2020- Poster Presentation, Peter Mesenbrink

Andrew Moon, Stephanie Watkins, Miguel Malespin, Cheryl Schoen, L Michael Weiss, Rohit Loomba, PJ Thulavath, Rajender Reddy, A. Sidney Barritt IV, Arun Sanyal, Brent Tetri. Weight loss and change in alanine aminotransferase (ALT) among patients with nonalcoholic fatty liver disease (NAFLD) receiving standard care in real world clinical practice: TARGET-NASH. EASL. August, 2020.

Kenneth Cusi, Michael Roden, A. Sidney Barritt IV, Roberto Firpi, Virginia Clark, Sam Klein, Anna S Lok, Philip Newsome, Karen Corbin, Miriam Vos, Rajender Reddy, Cheryl Schoen, Andrea Mospan, Jawahar Taunk, Kathleen Wyne, Brent Neuschwander-Tetri, Arun Sanyal. Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus. ADA. Virtual oral poster presentation. June, 2020.

Andrew M. Moon, Stephanie Watkins, Miguel Malespin, Cheryl Schoen, L. Michael Weiss, Rohit Loomba, Paul J. Thuluvath, K. Rajender Reddy, A. Sidney Barritt IV, Arun J. Sanyal, Brent A. Neuschwander-Tetri. Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH. Accepted to DDW. Abstract published Gastroenterology. May, 2020.

Malespin M, Barritt AS IV, Watkins S, Schoen C, Konerman M, Corbin K, Trinh HN, Weiss LM, Reddy R, Loomba R, Kemmer N, Lok AS. Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort. AASLD, Boston, MA. Oral Presentation. November, 2019.

AS Barritt IV, AS Lok, KR Reddy, LM Weiss, RJ Firpi, PJ Thuluvath, HN Trinh, S Djedjos, R Haubrich, A Billin, B Koch II, R Zink, AJ Sanyal, K Cusi, BA Neuschwander-Tetri. Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort. AASLD. Boston, Massachusetts. Poster Presentation. November, 2019.

Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort

Bryan Rudolph, Jacob Bilhartz, Cheryl Schoen, Praveen Selvakumar, Sirish Palle, Stavra Xanthakos, Patrick McKiernan, Alisha Mavis, A. Sidney Barritt IV, Miriam Vos. Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH. AASLD. Boston, Massachusetts. Poster Presentation. November, 2019.

Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH

A. Sidney Barritt IV, Stephanie Watkins, Brent Neuschwander-Tetri, Cheryl Schoen, Roshani Desai, Miriam Vos, Laura Malahias, Miguel Malespin, Philip Newsome, Rajender Reddy, Jawahar Taunk, Roberto Firpi, Arun Sanyal. Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH. AASLD. Boston, Massachusetts. Poster Presentation. November, 2019.

Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH

Vandana Khungar, Anna S. Lok, L. Michael Weiss, Paul Thuluvath, Kalyan Ram Bhamidimarri, Derek Gazis, Laura Malahias, K. Rajender Reddy. The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease. EASL. Vienna, Austria. Poster Presentation. April, 2019.

The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease

Andrew M. Moon, Anna S. Lok, Roberto J. Firpi-Morell, K. Vandana Khungar, Huy Ngoc Trinh, Justin T. Kupec, Cheryl Schoen, Laura Malahias, A. Sidney Barritt IV. Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity. EASL. Vienna, Austria. Poster Presentation. April, 2019.

Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity

Ethan Weinberg, Huy N. Trinh, Roberto J Firpi, Kalyan Ram Bhamidimarri, Samuel Klein, Laura Malahias, Richard C. Zink, Anna Lok. Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD. EASL. Vienna, Austria. Poster Presentation. April, 2019.

Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD

Roshani Desai, Arun Sanyal, Miriam Vos, Cheryl Schoen, Nikki Nicholson, Miguel Malespin, Philip Newsome, Brent A. Neuschwander-Tetri. Characterization of polypharmacy in patients with NAFLD. AASLD. San Francisco, CA. Poster Presentation. November, 2018.

Characterization of polypharmacy in patients with NAFLD

Cusi K, Barritt AS IV, Firpi R, Klein S, Lok AS, Loomba R, Malahias L, Reddy KR, Schoen C, Taunk J, Neuschwander-Tetri BA, Wyne K, Sanyal AJ. Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM). ADA. Orlando, Florida. Poster Presentation. June, 2018.

Palle S, Bilhartz J, Lavine J, Malahias L, Miloh T, Rudolph B, Schoen C, Xanthakos SA, McKiernan P, Vos MB. Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH. DDW. Washington, DC. Poster Presentation. June, 2018.

Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH

Sanyal A, Cusi K, Firpi-Morell R, Gitlin N, Levy C, Malahias L, Reddy KR, Schoen C, Weiss LM, Lok AS. Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease. DDW. Washington, DC. Poster Presentation. June, 2018.

Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease

deLemos A, Barritt AS IV, Bhamidimarri KR, Landis C, Malahias L, Malespin M, Schoen C, Taunk J, Thuluvath P, Trinh HN, Neuschwander-Teteri BA. Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH. DDW. Washington, DC. Poster Presentation. June, 2018.

Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH

Vos MB, Bilhartz J, Malahias L, McKiernan P, Miloh T, Palle S, Rudolph B, Schoen C, Xanthakos SA. ALT Elevation in Children with Nonalcoholic Fatty Liver Disease Commonly Surpasses Levels Reported in the Literature. Pediatric Academic Societies Meeting. Toronto, Canada. Oral Presentation. May, 2018.

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Newschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. AMCP. Boston, MA. Poster Presentation. April, 2018.

Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH

Sanyal A, Cusi K, Firpi-Morell R, Gitlin N, Levy C, Malahias L, Reddy KR, Schoen CL, Weiss LM, Lok AS. Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease. EASL. Paris, France. Poster Presentation. April, 2018.

Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (1)

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JEM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. NASH-TAG Conference. Park City, Utah. Poster Presentation. January, 2018.

Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (1)

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. HEP DART Conference. Kona, Hawaii. Poster Presentation. December, 2017.

Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (2)

Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. AASLD. Washington, DC. Poster Presentation. October, 2017.

Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (3)

Vos MB. The Trans-Atlantic Pediatric TARGET-NASH Study: Advancing Clinical Care for Pediatric NAFLD. International Conference on Fatty Liver. Seville, Spain. Oral Presentation. June, 2017.

Barritt AS IV, Cusi K, Klein S, Crawford JEM, DeMuth GE, Malahias L, Neuschwander-Tetri BA, Sanyal A, Vos, MB. Design and Rationale for a Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study. International Conference on Fatty Liver. Seville, Spain. Poster Presentation. June, 2017.

Design and Rationale for a Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study

Vos MB. A real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH Study. NASH Biomarkers Workshop 2017. Washington, DC. Oral Presentation. May, 2017.

Vos MB, Barritt AS IV, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A. A Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study. NASH Biomarkers Workshop 2017. Washington DC. Poster Presentation. May, 2017.

7

29 Dermatology

Maui Derm 2024: Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS

Jonathan I. Silverberg, MD, PhD, MPH, Keith D. Knapp, PhD, Breda Munoz, PhD, Julie M. Crawford, MD, Brian Calimlim, DrPH, MS, BS, Ayman Grada, MD, MHA, Amy S. Paller, MD, MS, on behalf of the TARGET-DERM Investigators. The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: Real-world Insights from TARGET-DERM AD. RAD Conference. Poster Presentation. May, 2023.

RAD 2023: The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: Real-world Insights from TARGET-DERM AD

Lara Wine Lee, Keith Knapp, Breda Munoz, Anthony Perez, Chibuzo Obi, Brian Calimlim, Ayman Grada, Jonathan I. Silverberg. Healthcare disparities in atopic dermatitis: insights from TARGET-DERM registry. RAD Conference. Poster Presentation. May, 2023.

RAD 2023: Healthcare disparities in atopic dermatitis: insights from TARGET-DERM registry

Haft M, Knapp K, Claxton A, Hernandez B, Balu S, Schneider S, Silverberg J, Thaci D, Eichenfield L. Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry. Hawaii Derm Seminar. Poster Presentation. February, 2023.

Haft M, Knapp K, Claxton A, Hernandez B, Balu S, Schneider S, Silverberg J, Thaci D, Eichenfield L. Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry. Winter Clinical Miami. Poster Presentation. February, 2023.

Haft M, Knapp K, Claxton A, Hernandez B, Balu S, Schneider S, Silverberg J, Thaci D, Eichenfield L. Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry. Winter Clinical Hawaii. Poster Presentation. January, 2023.

Winter Clinical Hawaii 2023: Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry

Paller A, Knapp K, Munoz B, Kalam A, Claxton A, Balu S, Schneider S, Eichenfield L. Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry. Hawaii Derm Seminar. Poster Presentation. February, 2023.

Paller A, Knapp K, Munoz B, Kalam A, Claxton A, Balu S, Schneider S, Eichenfield L. Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry. Winter Clinical Miami. Poster Presentation. February, 2023.

Paller A, Knapp K, Munoz B, Kalam A, Claxton A, Balu S, Schneider S, Eichenfield L. Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry. Maui Dermatology Hawaii. Poster Presentation. January, 2023.

Maui Derm 2023: Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET DERM Registry

Jonathan I. Silverberg, Brenda Simpson, Katrina Abuabara, Emma Guttman-Yassky, Brian Calimlim, Colleen Wegzyn, Whitney Krueger, Amy Gamelli, Breda Munoz, Julie M. Crawford, Lawrence F. Eichenfield on behalf of TARGET-DERM Investigators. Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: A Cross Sectional Study from the TARGET-DERM AD Cohort. Fall Clinical Dermatology Conference. Poster Presentation. October, 2022.

Lawrence F. Eichenfield, Katrina Abuabara, Michael S. Chapman, Emma Guttman Yassky, Brian Calimlim, Colleen Wegzyn, Whitney Krueger, Amy Gamelli, Breda Munoz, Rachel W. Faller, Julie M. Crawford, Jonathan I. Silverberg on behalf of TARGET DERM Investigators. Burden of Disease is Positively Associated with Disease Severity in Atopic Dermatitis. Fall Clinical Dermatology Conference. Poster Presentation. October, 2022.

Wine Lee, L, Knapp K, Munoz B, Perez A, Obi C, Calimlim B, Grada , A, Silverberg J. Healthcare Disparities in Atopic Dermatitis: Insights from TARGET DERM Registry. Fall Clinical Dermatology Conference. Poster Presentation. October, 2022.

Haft M, Eichenfield D, Fried M, Knapp K, Hernandez B, Kim Y, Balu S, Schneider S, Paller A, Silverberg J, Thaci D, Eichenfield L. Use of Advanced Systemic Therapy in Patients with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry. Fall Clinical Dermatology Conference. Poster Presentation. October, 2022.

Jonathan I Silverberg, Brenda Simpson, Katrina Abuabara, Emma Guttman-Yassky, Brian Calimlim, Colleen Wegzyn, Whitney Krueger, Amy Gamelli, Breda Munoz, Janet S Hildebrand, Julie M Crawford, Lawrence F Eichenfield. Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort. RAD Conference. Virtual Oral Poster Presentation. December, 2021.

RAD 2021: Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort

Lawrence F Eichenfield, Katrina Abuabara, Michael S Chapman, Emma Guttman-Yassky, Brian Calimlim, Colleen Wegzyn, Whitney Krueger, Amy Gamelli, Breda Munoz, Rachel W Faller, Julie M Crawford, Jonathan I Silverberg. Burden of Disease is Positively Associated with Disease Severity in Atopic Dermatitis. RAD Conference. Virtual Poster Presentation. December, 2021.

RAD 2021: Burden of Disease is Positively Associated with Disease Severity in Atopic Dermatitis

Katrina Abuabara, Jonathan I Silverberg, Eric L Simpson, Amy S Paller, Lawrence F Eichenfield, Robert Bissonnette, James Krueger, John E Harris, Laura Dalfonso, Janet S Hildebrand, Julie M Crawford, Diamant Thaci, Emma Guttman-Yassky. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. RAD Conference. Virtual Poster Presentation. December, 2020.

RAD 2020: International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale

1

16 Gastroenterology

Edward L. Barnes, Miguel Regueiro, Shweta Shah, Harris A. Ahmad, Derek Gazis, Heather L. Morris, Julie M. Crawford, Megan Lutz, Marla C. Dubinsky, David T. Rubin, on behalf of the TARGET-IBD Investigators. Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD. ACG. Poster Presentation. October, 2023.

ACG2023 - Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD

Millie D. Long MD, Marla C. Dubinsky MD, Miguel Regueiro MD, Javier Zambrano MD, Cynthia Theigs RPh, Jenny Griffith PharmD, Wesley Matthias PharmD, Michelle Kujawski PhD, Dolly Sharma PhD, Robert Pearson PharmD, Julie M. Crawford MD, Laura Dalfonso MBA, Anthony Perez PhD, Derek Gazis MS, Michael W. Fried MD, Heather L. Morris PhD, David T. Rubin MD. The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn’s Disease in TARGET IBD. AIBD. Poster Presentation. December, 2022.

AIBD 2022- The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn’s Disease in TARGET IBD

Benjamin L. Cohen, Benjamin Click, Edward L. Barnes, Ryan Ungaro, Komal Gupte-Singh, Jinender Kumar, Garrett Lawlor, James Canavan, Julie M. Crawford, Breda Munoz, Anthony Perez, Heather L. Morris, Millie D. Long, Bruce Sands. Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD. AIBD. Poster Presentation. December, 2022.

AIBD 2022- Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD

Benjamin H. Click, Eric Mao, Harris Ahmad, James Canavan, Ying Qiu, Cindy Theigs, Julie M. Crawford, Millie D. Long, TARGET-IBD Investigators. Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis (Su1537). DDW. Poster Presentation. Abstract printed in Gastroenterology and GIE: Gastrointestinal Endoscopy. May, 2022.

DDW 2022: New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients who had Histologic Inflammation on Baseline Biopsy

Harris Ahmad, James B. Canavan, Benjamin Click, Jiyoon Choi, Derek Gazis, Janet S. Hildebrand, Julie M. Crawford, Millie D. Long. Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis. UEG Week. Virtual Poster Presentation. October, 2021.

UEG Week 2021- Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis

Megan Lutz, Freddy Caldera, Katie Schroeder, Derek Gazis, Janet S. Hildebrand, Julie M. Crawford, Millie D. Long, Edward Barnes. Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort. DDW. Virtual Poster Presentation. May, 2021. Poster of Distinction Award.

DDW 2021- TARGET-IBD Poster, Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort

Benjamin L. Cohen, Jenny Griffith, Cindy Theigs, Kim L. Isaacs, Julie Mallory Crawford, Janet S. Hildebrand, Derek Gazis, Millie D. Long. Biologic-naïve Patients with Crohn’s Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort. DDW. Virtual Poster Presentation. May, 2021.

DDW 2021- TARGET-IBD Poster, Biologic-naïve Patients with Crohn’s Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort

Edward L. Barnes, Harris Ahmad, Joe Zhu, Antoine Sreih, James B. Canavan, Joehl Nguyen, Derek Gazis, Janet S. Hildebrand, Julie M. Crawford, Millie D. Long, John S. Hanson. Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. AIBD. Virtual Poster Presentation. December, 2020.

Benjamin H. Click, Edward L. Barnes, Benjamin Cohen, Miguel D. Regueiro, Marla C. Dubinsky, John S. Hanson, Bruce E. Sands, David T. Rubin, Srikar Guntaka, Derek Gazis, Julie M. Crawford, Millie D. Long. Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD. DDW. Abstract published in Gastroenterology. May, 2020.

Edward L. Barnes, John S. Hanson, Miguel Regueiro, Sumona Saha, Bruce E. Sands, David T. Rubin, Marla C. Dubinsky, Corey A. Siegel, Derek R. Gazis, Julie M. Crawford, Millie D. Long. Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort. ACG. San Antonio, Texas. Poster Presentation. October, 2019. Presidential Poster Award, Outstanding Poster Presenter Award (Dr. Barnes).

Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort

Edward L. Barnes, John S. Hanson, Miguel Regueiro, Sumona Saha, Bruce E. Sands, David T. Rubin, Marla C. Dubinsky, Corey A. Siegel, Derek R. Gazis, Julie M. Crawford, Millie D. Long. Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort. ECCO. Vienna, Austria. Encore Oral Poster Presentation. February, 2020. Best Digital Oral Presentation Award (Dr. Sands).

Nitin Gupta, Bruce E. Sands, Miguel Regueiro, Marla C. Dubinsky, David T. Rubin, John S. Hanson, Faten Aberra, Michael Weiss, Stephanie Watkins, Derek Gazis, Millie D. Long. Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study. ECCO. Vienna, Austria. Encore ACG Poster Presentation. February, 2020.

Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study

Nitin Gupta, Bruce E. Sands, Miguel Regueiro, Marla C. Dubinsky, David T. Rubin, John S. Hanson, Faten Aberra, Michael Weiss, Stephanie Watkins, Derek Gazis, Millie D. Long. Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study. ACG. San Antonio, Texas. Poster Presentation. October, 2019.

Millie D. Long, David T. Rubin, Marla C. Dubinsky, John Hanson, Michael Weiss, Edward L. Barnes, Sumona Saha, Charles Moser, Robert Sandefur, Bruce E. Sands. Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD. ACG. Philadelphia, Pennsylvania. Poster Presentation. October, 2018.

Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD

1

13 Pharmacoepidemiology

Jennifer Christian, PharmD, PhD, FISPE; Priscilla Velentgas, MS, PhD; Cynthia J. Girman, DrPH, FISPE; Anne Trontell, MPH, MD; Jay Park, PhD; Kathleen Hurwitz, ScD. Methods and New Approaches in Pragmatic Trials. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Skills Course Session. August, 2023.

David Pritchard, PhD, MS. Characterizing the Distribution of Multiple Negative Control Outcome Risk Differences. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Poster Presentation. August, 2023.

Nuvan Rathnayaka. Orthogonalized Regression for Causal Inference: A Pharmacoepidemiologist’s Dream? International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2023.

Catherine Weiner. An Analytic Method to Weight Longitudinal Treatment Patterns for Visualization with Sankey Diagrams. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2023.

Nuvan Rathnayaka, Catherine Wiener, Alexander S. Breskin, Angela Cook, M. Alan Brookhart. In-Hospital Treatment Patterns Among Patients Hospitalized with COVID-19 in the United States. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Spotlight Poster Presentation. August, 2022.

M. Alan Brookhart, Catherine Wiener, Alexander S. Breskin. Discharged Where? The Importance of Understanding Discharge Dispositions When Estimating In-Hospital Mortality. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Poster Presentation. August, 2022.

David Pritchard, Matthew Phelan, M. Alan Brookhart. Fracture Risk Estimation in Post-menopausal Women: A Comparison of Machine Learning Methods and Software Systems. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2022.

Nuvan Rathnayaka, Alexander S. Breskin, Angela Cook, Catherine Wiener, M. Alan Brookhart. Risk Factors for Mortality and Intensive Care Requirements Among Pediatric Patients Hospitalized with COVID-19 in the United States. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2022.

Alexander S. Breskin, Catherine Wiener, M. Alan Brookhart. The Effect of Remdesivir for The Treatment of COVID-19 on Mortality Among Hospitalized Patients. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2022.

Alexander S. Breskin. One Design to Rule Them All: The Clone-Censor-Weight Design as a General Framework for Epidemiologic Studies. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2022.

Lydia Feinstein, Alexander S. Breskin, Peter S. Samai, M. Alan Brookhart. Negative Control Outcomes to Assess the Comparability of Biologics versus Small-molecule Therapeutics for Osteoporosis: Considerations for Differential Non-adherence. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2022.

Andrew G. Allmon, Samantha Eiffert, Alexander S. Breskin. The impact of parametric assumptions on the bias-variance tradeoff for causal analysis of time-to-event outcomes. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. August, 2022.

Use of negative control outcomes to detect mismeasured confounders in administrative data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Poster Presentation. August, 2021.

Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Poster Presentation. September, 2020.

History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Poster Presentation. September, 2020.

Using Negative Control Outcomes to Assess the Comparability of Osteoporosis Treatment Groups. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. 2018.

Performance of machine learning algorithms for hysterectomy risk prediction among women with endometriosis in the United States. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Oral Presentation. 2018.

11

6 Primary Biliary Cholangitis (PBC)

Elizabeth Carey, Helen Smith, Megan McLaughlin, April Thompson, Andrea Mospan, Robert Sandefur, Richard C. Zink, W. Ray Kim, Cynthia Levy. The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC. APASL. Encore Virtual Poster Presentation. March, 2022.

Marlyn J. Mayo, Andrea Mospan, Helen Smith, Megan McLaughlin, April Thompson, Robert Sandefur, Richard C. Zink, Christopher Bowlus, Cynthia Levy. Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC. APASL. Encore Virtual Poster Presentation. March, 2022.

AASLD 2020, The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC

AASLD 2020, Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC

Marlyn J. Mayo, Christopher L. Bowlus, Elizabeth J. Carey, Ester C. Little, Karen Deane, Richard Zink, Robert Sandefur, W. Ray Kim, Cynthia Levy. Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real- world cohort. DDW. San Diego, California. Poster Presentation. May, 2019.

Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real- world cohort.

Cynthia Levy, Marlyn J. Mayo, Elizabeth J. Carey, Ester C. Little, W. Ray Kim, Karen Deane, Richard Zink, Robert Sandefur, Christopher L. Bowlus. Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort. DDW. San Diego, California. Poster Presentation. May, 2019.

Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort.

Marlyn J. Mayo, Christopher L. Bowlus, Elizabeth J. Carey, Ester C. Little, Karen Deane, Richard Zink, Robert Sandefur, W. Ray Kim, Cynthia Levy. Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real- world cohort. EASL. Vienna, Austria. Poster Presentation. April, 2019.

Cynthia Levy, Marlyn J. Mayo, Elizabeth J. Carey, Ester C. Little, W. Ray Kim, Karen Deane, Richard Zink, Robert Sandefur, Christopher L. Bowlus. Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort. EASL. Vienna, Austria. Poster Presentation. April, 2019.

Change in lipids: characteristics and response to Obeticholic Acid (OCA) in TARGET-PBD, a diverse, large United States (US) real-world cohort

Carey EJ, Levy C, Mayo MJ, Bowlus CL, Deane K, Sandefur RA, Laliberte PH, Zink RC, Kim WR. Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC). AASLD. San Francisco, California. Poster Presentation. November, 2018.

Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC)

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Iloeje U, Erickson M, Strauss M, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC. DDW. Washington, DC. Poster Presentation. June, 2018.

Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC. DDW. Washington, DC. Poster Presentation. June, 2018.

Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Iloeje U, Erickson M, Strauss M, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC. EASL. Paris, France. Poster Presentation. April, 2018.

Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (1)

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC. EASL. Paris, France. Poster Presentation. April, 2018.

13 Hepatocellular Carcinoma (HCC)

Singal A, Fried MW, Colombo M, Mospan AR, Morris HL, Cabrera R, Kelley K, Mehta N, Sangro B, on behalf of TARGET-HCC/DAA-PASS Investigators. A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS. EASL Congress 2023. Poster Presentation. June, 2023.

EASL 2023- A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS

Roniel Cabrera, Amit Singal, Massimo Colombo, Anthony El-Khoueiry, R. Kate Kelley, Hannah Lee, Laura Malahias, Tim Meyer, Pippa Newell, Neehar Parikh, Bruno Sangro, K Rajender Reddy, Richard Zink, Adrian Di Bisceglie.Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC). EASL. Vienna, Austria. Poster Presentation. April, 2019.

Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC)

Neehar D. Parikh, Laura Malahias, Robert S. Brown Jr., Roniel Cabrera, Patricia Denise Jones, Charles Landis, Hannah Lee, Parvez Mantry, Edward Mena, Nishant Poddar, K. Rajender Reddy, Roshan Shrestha, Paul Thuluvath, Richard C. Zink, Amit G. Singal. Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US. ASCO-GI. San Francisco, California. Poster Presentation. January, 2019.

Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US

3 Rheumatology

1 Osteoporosis

Min Kim, Vanessa Brunetti, Felicia Cosman, Jeffrey R Curtis, E. Michael Lewiecki, Matthew Phelan, Peter Samai, Michele T. McDermott, Tzu-Chieh Lin, M. Alan Brookhart, Kathleen Hurwitz. Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-fracture Treatment Among Commercially Insured Postmenopausal Women in the United States. American Society for Bone and Mineral Research (ASBMR). Oral Presentation. October, 2023.

$ASBMR 2023- Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-fracture Treatment Among Commercially Insured Postmenopausal Women in the United States$

1 Chronic Hepatitis B (HBV)

DE Bernstein, HN Trinh, ER Schiff, CI Smith, RC Zink, AS Lok. Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study. HEP DART. Kauai, Hawaii. Encore Poster Presentation. December, 2019.

Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study (1)

DE Bernstein, HN Trinh, ER Schiff, CI Smith, RC Zink, AS Lok. Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study. AASLD. Boston, Massachusetts. Poster Presentation. November, 2019.

2 Oncology

Agreement between electronic health records and administrative claims data for patients with multiple myeloma. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Conference. Poster Presentation. 2018.

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States. American Society of Hematology Conference. Oral Presentation. 2017.

1 Hematology

Real-world patterns of romiplostim treatment in adults with primary immune thrombocytopenia in the United States. Thrombosis & Hemostasis Summit. Poster Presentation. 2018.

1 Cardiovascular Disease

Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models

Lipids testing trends before and after hospitalization for myocardial infarction among adults in the United States, 2008-2019. European Society of Cardiology Congress. Oral Presentation. August, 2021.

Lipid testing trends in the US before and after the release of the 2013 ACC/AHA cholesterol guidelines. American Heart Association Conference. Poster Presentation. November, 2019.

1

2 COVID-19

Fayolah Richards, Antoine C. El Khoury, Chantal Holy, Lilla Di Scala, Brandon J. Patterson, Andrea R. Mospan, Julie M. Crawford, Breda Munoz, Heather L. Morris, Michael W. Fried. Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19. ISPOR. Poster Presentation. May, 2022.

ISPOR 2022: Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19

Patterson B, Munoz B, Fried M, Morris H, Mospan A, Crawford J, Richards F, Di Scala L, Holy C, El Khoury A. Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19. AMCP. Virtual Poster Presentation. March, 2022.

AMCP 2022- Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19

Elizabeth C. Verna, Charles Landis, Robert S. Brown, Jr, Andrea R. Mospan, Julie M. Crawford, Janet Hildebrand, Heather L. Morris, Breda Munoz, Michael W. Fried, K. Rajender Reddy. Factors Associated with Readmission Following COVID-19 Hospitalization. RespiDART and HIV DART. Virtual Poster Presentation. December, 2020.

RespiDART 2020 - Factors Associated with Readmission Following COVID-19 Hospitalization

1

2

Featuring Target RWE Authors

Statistics & Methodology

Alexander Breskin, PhD. Fusion Designs for Indirect Treatment Effects. Society for Epidemiology Research (SER) annual meeting. Oral Presentation. June, 2022.

Lydia Feinstein, PhD. On Teaching Advanced Epidemiologic Methods. Society for Epidemiologic Research (SER) annual meeting. Poster Presentation. June, 2022.

Stephen R Cole, Jessie K Edwards, Alexander Breskin, Samuel Rosin, Paul N Zivich, Bonnie E Shook-Sa, Michael G Hudgens. Illustration of Two Fusion Designs and Estimators Get access Arrow. American Journal of Epidemiology, April 2022; doi.org/10.1093/aje/kwac067.

Alexander Breskin, Stephen R. Cole, Jessie K. Edwards, Ron Brookmeyer, Joseph J. Eron, Adimora A. Adimora. Fusion designs and estimators for treatment effects. Statistics in Medicine, March 2021; doi.org/10.1002/sim.8963.

Matthew L. Maciejewski, PhD; M. Alan Brookhart, PhD. Using Instrumental Variables to Address Bias from Unobserved Confounders. JAMA, May 2019; doi:10.1001/jama.2019.5646.

3

2 HIV

Faith Ussery, Pamela Bachanas, Mary Grace Alwano, Refeletswe Lebelonyane, Lisa Block, Kathleen Wirth, Gene Ussery, Baraedi Sento, Tendani Gaolathe, Etienne Kadima, William Abrams, Tebogo Segolodi, Shannon Hader, Shahin Lockman, Janet Moore. HIV Incidence in Botswana Rural Communities With High Antiretroviral Treatment Coverage: Results From the Botswana Combination Prevention Project, 2013-2017. Journal of acquired immune deficiency syndromes, September 2022; doi: 10.1097/QAI.0000000000003017.

Stephen C Resch, Julia H A Foote, Kathleen E Wirth, Arielle Lasry, Justine A Scott, Janet Moore, Fatma M Shebl, Tendani Gaolathe, Mary K Feser, Refeletswe Lebelonyane, Emily P Hyle, Mompati O Mmalane, Pamela Bachanas, Liyang Yu, Joseph M Makhema, Molly Pretorius Holme, Max Essex, Mary Grace Alwano, Shahin Lockman, Kenneth A Freedberg. Health Impact and Cost-Effectiveness of HIV Testing, Linkage, and Early Antiretroviral Treatment in the Botswana Combination Prevention Project. Journal of acquired immune deficiency syndromes, August 2022; doi: 10.1097/QAI.0000000000002996.

Paul N Zivich, Stephen R Cole, Jessie K Edwards, Bonnie E Shook-Sa, Alexander Breskin, Michael G Hudgens. Bridged treatment comparisons: an illustrative application in HIV treatment. arXiv, June 2022 doi.org/10.48550/arXiv.2206.04445.

Sara N. Levintow, Brian W. Pence, Kimberly A. Powers, Teerada Sripaipan, Tran Viet Ha, Viet Anh Chu, Vu Minh Quan, Carl A. Latkin, Vivian F. Go. Estimating the Effect of Depression on HIV Transmission Risk Behaviors Among People Who Inject Drugs in Vietnam: A Causal Approach. AIDS and Behavior, August 2020; doi.org/10.1007/s10461-020-03007-9.

4 Pharmacoepidemiology

Alexander Breskin, Andrew Edmonds, Stephen R Cole, Daniel Westreich, Jennifer Cocohoba, Mardge H Cohen, Seble G Kassaye, Lisa R Metsch, Anjali Sharma, Michelle S Williams, Adaora A Adimora. G-computation for policy-relevant effects of interventions on time-to-event outcomes. International Journal of Epidemiology, December 2020; doi.org/10.1093/ije/dyaa156.

Alexander Breskin, Eleanor J Murray. Commentary: Compositional data call for complex interventions. International Journal of Epidemiology, August 2020; doi.org/10.1093/ije/dyaa084.

Alexander Breskin, Daniel Westreich, Stephen R Cole, Jessie K Edwards. Using Bounds to Compare the Strength of Exchangeability Assumptions for Internal and External Validity. American Journal of Epidemiology, March 2019; doi.org/10.1093/aje/kwz060.

Anne M. Butler, Jonathan V. Todd, John M. Sahrmann, Catherine R. Lesko, M. Alan Brookhart. Informative censoring by health plan disenrollment among commercially insured adults. Pharmacoepidemiology & Drug Safety, February 2019; doi.org/10.1002/pds.4750.

Stephen R Cole, Michael G Hudgens, Jessie K Edwards, M Alan Brookhart, David B Richardson, Daniel Westreich, Adaora A Adimora. Nonparametric Bounds for the Risk Function. American Journal of Epidemiology, January 2019; doi.org/10.1093/aje/kwz013.

Breskin, Alexander; Cole, Stephen R.; Hudgens, Michael G. A Practical Example Demonstrating the Utility of Single-world Intervention Graphs. Epidemiology, May 2018; doi: 10.1097/EDE.0000000000000797.

Julia B. Ward, Erline Martinez-Miller, Brian Matlaga, Lydia Feinstein. Disparities in Prevalence of Urinary Incontinence among a Nationally Representative Sample of Men, 2005-2016: Findings from the Urologic Diseases in America Project. Society for Epidemiologic Research (SER) annual meeting. Poster Presentation. June, 2022.

6

1

Download the Full List

Get access to Target RWE's comprehensive publications, download the complete list today!

Download the Full List

Get access to Target RWE's comprehensive publications, download the complete list today!